Novel peptides targeting the hepatocyte growth factor receptor c-Met for the treatment of cancer

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 5, 2005, Pages 621-625

  Michaud, Neil R ^a  

^a PFIZER INC   (United States)

Author keywords

c Met; Cancer; Hepatocyte growth factor (HGF); Kinase inhibitor; Peptide antagonist; Therapeutic monoclonal antibody; Tumour

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1A3.3.13; MONOCLONAL ANTIBODY 5D5.11.6; PEPTIDE DERIVATIVE; PHA 665752; PHOSPHOTRANSFERASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR ANTAGONIST; SU 11274; UNCLASSIFIED DRUG; XL 880;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; HUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 19044390556     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.5.621     Document Type: Article

References (13)

1. RONG S, BODESCOT M, BLAIR D et al.: Tumorigenicity of the Met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol. (1992) 12:5152-5158.
2. TRUSOLINO L, COMOGLIO PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer (2002) 2:289-300.
3. BIRCHMEIER C, BIRCHMEIER W, GHERARDI E, VAN DE WOUDE GF: Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. (2003) 4:915-925.
4. SATTLER M, MA PC, SALGIA R: Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat. Res. (2004) 119:121-138.
5. BUSSOLINO F, DI RENZO MF, ZICHE M et al.: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. (1992) 119:629-641.
6. SAUCIER C, KHOURY H, LAI K-MV et al.: The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc. Natl. Acad. Sci. USA (2004) 101:2345-2350.
7. SATTLER M, PRIDE YB, MAP et al.: A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. (2003) 63:5462-6459.
8. CHRISTENSEN JG, SCHRECK R, BURROWS J et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. (2003) 63:7345-7355.
9. CAO B, SU Y, OSKARSSON M et al.: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA (2001) 98:7443-7448.
10. MATSUMOTO K, NAKAMURA T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. (2003) 94:321-327.
11. CHAN AM-L, RUBIN JS, BOTTARO DP, HIRSCHFIELD DW, CHEDID M, AARONSON SA: Identification of a competitive HGF antagonist encoded by an alternative transcript. Science (1991) 254:1382-1385.
12. LADNER RC, SATO AK, GORZELANY J, DE SOUZA M: Phage display-derived peptides as therapeutic alternatives m antibodies. Drug Discov. Today (2004) 15:525-529.
13. MA PC, SCHAEFER E, CHRISTENSEN JG, SALGIA R: A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin. Cancer Res. (2005) 11:2312-2319.